腹腔免疫化疗治疗老年胃肠道肿瘤患者的疗效观察  

Clinical effects of abdominal cavity chemoimmunotherapy with elderly patients with gastrointestinal tumor

作　　者：陈东升[1] 吴光兴[1] 

机构地区：[1]广东省湛江中心人民医院肿瘤防治中心,湛江524037

出　　处：《中国肿瘤临床与康复》2014年第2期181-183,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨老年胃肠道肿瘤患者采用腹腔免疫化疗的临床疗效和生活质量。方法将80例老年胃肠道肿瘤患者随机分为观察组(40例)和对照组(40例),观察组患者采用腹腔免疫化疗,对照组患者采用腹腔化疗,分析两组患者治疗前后消化病生存质量指数(GLQI)、治疗后卡氏行为状态评分(KPS)以及不良反应发生情况。结果观察组患者的好转率优于对照组(P<0.01)。观察组患者治疗后1周和4周的GLQI高于对照组(P<0.05),并且胃肠道反应和乏力的发生率低于对照组(P<0.05)。结论腹腔免疫化疗能够提高老年胃肠道肿瘤患者的疗效,增强患者的免疫功能,减少不良反应,改善患者的生活质量,可作为老年胃肠道肿瘤患者治疗的优选方案。Objective To explore the effects and quality of life of abdominal cavity chemoimmuno- therapy of elderly patients with gastrointestinal tumor. Methods 80 elderly patients with gastrointestinal tumor were randomly divided into 2 groups, 40 cases in each group. One group was treated with abdominal cavity chemotherapy, and the other group was treated with abdominal cavity chemoimmunotherapy. The GLQI score, KPS score and the adverse reaction of patients in the two groups before and after treatment were compared. Results The improvement rate of the observational group was better than that of the control group after treatment（ P 〈 0. 01 ）. The GLQI quality of life scores in the observational group after one or four weeks treatment were higher than that of the control group（P 〈 0. 05）. The rate of gastrointestinal reaction and weakness of the observational group was lower than that of the control group （ P 〈 0. 05 ）. Conclusions Abdominal cavity chemoimmunotherapy can improve the curative effects of elderly patients with gastroin- testinal tumor, enhance the immune function of patients, reduce the adverse reactions, and improve the quality of life of patients. It can be used as the optional scheme for elderly patients with gastrointestinal tumor.

关 键 词：腹腔免疫化疗 老年人 胃肠道肿瘤 治疗结果 

分 类 号：R735[医药卫生—肿瘤]